Comparison ofHER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference48 articles.
1. The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
2. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
3. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
4. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
5. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Cited by 136 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. POTENTIAL IMPACT OF HERCEPTEST™ MAB PHARMDX (DAKO OMNIS) (GE001) IN BREAST CANCER DIAGNOSIS;Polish Journal of Pathology;2023
2. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial;Scientific Reports;2021-07-02
3. Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody;Antibodies;2020-09-18
4. Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle;Diagnostics;2020-06-04
5. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer;International Journal of Molecular Sciences;2020-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3